614 McKinley Place N.E.
131 articles with Bio-Techne
Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies.
Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2018.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2018.
Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc.
Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess.
Bio-Techne To Host Conference Call On August 7, 2018 To Announce Fourth Quarter 2018 Financial Results
Bio-Techne Corporation announced that management will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. CDT to review fourth quarter 2018 financial results.
Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets
Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results
Validated tissue bank and pre-collected immuno-oncology datasets speed up investigative research projects through to clinical development...
The transaction is expected to close in early July and to be financed through available cash on hand.
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the William Blair 38th Annual Growth Stock Conference.
Bio-Techne Corporation reported its financial results for the third quarter ended March 31, 2018.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2018.
Bio-Techne has a leading role supporting autophagy research.
Bio-Techne has expanded the automation capabilities of its popular Advanced Cell Diagnostics (ACD)-branded RNAscope® in situ hybridization (ISH) technology with the launch of several new and updated assays.
Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract
Bio-Techne has released MimEX™ GI, a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface.
Bio-Techne today reported its financial results for the second quarter ended December 31, 2017.
The investment underscores BioAgilytix's commitment to effectively addressing customers' evolving biomarker assay needs.
Bio-Techne to Host Conference Call on February 6, 2018 to Announce Second Quarter 2018 Financial Results
Bio-Techne today announced that management will host a conference call on February 6, 2018, at 8:00 a.m. CST to review second quarter 2018 financial results.
Several reagents from Vector Laboratories are currently available at novusbio.com for distribution within the continental U.S.
Bio-Techne announced today that it has acquired all of the stock of Atlanta Biologicals and its affiliated company, Scientific Ventures.